Massive Development In Antacid Market: New Study Shows That Antacid Enhance Blood Sugar Control In Diabetic Patients
Type 2 Diabetes is a condition that touches approximately 10% of the world population and thus is a constant global concern. To promote patients to keep their blood sugar levels under control, doctors prescribe things such as diet and lifestyle changes, insulin, or even diabetes medication. However, the disease still affects the day-to-day lives of patients and the families involved. There is a dire requirement for a medicine that is more effective than the ones already on the market. To this effect, recent data has revealed that common over-the-counter antacids could be a potential treatment for improving glucose levels.
A recent study has assessed the efficacy of the medicine and brought forth that antacids improve blood sugar in people who have diabetes. However, they cannot reduce the risk of diabetes from the general population. The evidence of the ability of antacids for treating diabetes might bring a boost to the Antacid Market and may help several patients live a better quality of life.
The research showed that prescribing antacids along with add-on to standard care resulted in superior effects in decreasing hemoglobin A1C (HbA1c) levels and fasting blood sugar in contrast to the standard therapy. When the antacid was taken by non-diabetic people, it was noted that the intake did not significantly change their risk of not contracting the disease.
The team performed a meta-analysis on the effects of PPIs (Proton Pimp Inhibitors) – a type of antacid medication that is generally used against blood sugar levels with diabetic people. They also noted if the medications could help prevent the development of the disease in the general population. The overall analysis included seven studies with 342 participants for glycemic control and five studies including 244, 439 participants for risk of developing diabetes.
Researchers discovered that intake of antacids resulted in a reduction of A1c (HbA1c) levels by 0.36% within diabetic people. In addition, the fasting blood sugar was lowered by 10 mg/dl as per the results from the seven clinical trials. Among non-diabetic people, the results from the five studies demonstrated that antacids were not effective in reducing the risk of incidental diabetes.
The research team revealed that the aim of their study is to basically provide people with diabetes with the knowledge that the commonly used antacids could balance their blood sugar levels while also lowering their glucose effect. This is also an add-on that can be included in a doctor’s prescription to have better-desired effects on the health of diabetic people.
Other Related Reports:
Global Gastritis Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2027
Global Diabetic Gastroparesis Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026